BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bickel M, Lais C, Wieters I, Kroon FP, Doerr HW, Herrmann E, Brodt HR, Jung O, Allwinn R, Stephan C. Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. Scand J Infect Dis 2014;46:656-9. [PMID: 25004089 DOI: 10.3109/00365548.2014.922695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Kitchen M, Leierer G, Kistner O, Wodal W, Gisinger M, Zangerle R, Sarcletti M. High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria. Vaccine 2022;40:3948-53. [PMID: 35606234 DOI: 10.1016/j.vaccine.2022.05.004] [Reference Citation Analysis]
2 Chen YC, Zhou JH, Tian JM, Li BH, Liu LH, Wei K. Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety. Hum Vaccin Immunother 2020;16:612-22. [PMID: 31567058 DOI: 10.1080/21645515.2019.1672492] [Reference Citation Analysis]
3 Chang L, Lim BCW, Flaherty GT, Torresi J. Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med 2019;26:taz034. [PMID: 31066446 DOI: 10.1093/jtm/taz034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]